A study published in the British Journal of Pharmacology on 3 March, led by University of Queensland researchers Associate Professor Trent Woodruff and Dr John Lee, has found the drug “PMX205” extends the life of mice that have a SOD1 mutation, when administered before or during very early disease onset. More studies are now underway to determine the safety of PMX205 before it can be tested in humans. 'Pharmacological inhibition of complement C5a-C5a1 receptor signalling ameliorates disease pathology in the hSOD1G93A mouse model of amyotrophic lateral sclerosis' tttp://onlinelibrary.wiley.com/doi/10.1111/bph.13730/full
Postive results for PMX205 in mice with SOD1 mutation
Latest News
Calls for Urgent Action on Aged Care Assessment Tool
MND NSW supports MND Australia's calls for greater transparency about the outcome of the Government’s review of the Integrated Assessment Tool (I...
QALSODY (tofersen) Listed on the PBS
MND NSW and MND Australia have joined FightMND in welcoming the Australian Government's decision to list QALSODY (tofersen) on the Pharmaceutical Bene...
Top 5 Frequently Asked Questions from August 2026
A diagnosis of Motor Neurone Disease (MND) can raise many questions for the person receiving the diagnosis as well as their family, friends and suppor...
Thank You to Yarralumla Uniting Church
We'd like to say a big thank you to Bronwyn Hendy and the Yarralumla Uniting Church (YUC) for their Hymnfest and Afternoon Tea for MND fundraiser...